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Hepcidin is a liver-derivedpeptide hormone that controls sys-
temic iron homeostasis. Its expression is regulated by the bone
morphogenetic protein 6 (BMP6)/SMAD1/5/8 pathway and by
the proinflammatory cytokine interleukin 6 (IL6). Proteogly-
cans that function as receptors of these signaling proteins in the
liver are commonly decorated by heparan sulfate, but the poten-
tial role of hepatic heparan sulfate in hepcidin expression and
iron homeostasis is unclear. Here, we show that modulation of
hepatic heparan sulfate significantly alters hepcidin expression
and ironmetabolismboth in vitro and in vivo. Specifically, enzy-
matic removal of heparan sulfate from primary human hepato-
cytes, CRISPR/Cas9manipulation of heparan sulfate biosynthe-
sis in human hepatoma cells, or pharmacological manipulation
of heparan sulfate–protein interactions using sodium chlorate
or surfen dramatically reduced baseline and BMP6/SMAD1/5/
8-dependent hepcidin expression. Moreover inactivation of the
heparan sulfate biosynthetic gene N-deacetylase and N-sulfo-
transferase 1 (Ndst1) in murine hepatocytes (Ndst1f/fAlbCre)
reducedhepatichepcidinexpressionandcausedaredistributionof
systemic iron, leading to iron accumulation in the liver and serum
of mice. Manipulation of heparan sulfate had a similar effect on
IL6-dependent hepcidin expression in vitro and suppressed IL6-
mediated iron redistribution induced by lipopolysaccharide in
vivo. These results provide compelling evidence that hepatocyte
heparan sulfate plays a key role in regulating hepcidin expression
and iron homeostasis inmice and in human hepatocytes.
Hepcidin is the key peptide hormone regulating systemic
iron homeostasis, and it is expressed primarily in the liver. Hep-
cidin is produced as a prepropeptide and processed by the con-
vertase furin into the mature and active 25-amino acid peptide
before being secreted into the circulation. Circulating hepcidin
binds ferroportin, the only known cellular iron exporter (1),
resulting in its ubiquitination and subsequent degradation, thus
preventing dietary iron export from enterocytes and recycled
iron from red blood cells degraded by macrophages (2, 3).
A variety of stimuli trigger hepcidin expression, including
high tissue and plasma iron levels, inflammation, hypoxia, and
erythropoiesis (4). Iron-dependent hepcidin expression is con-
trolled primarily through BMP/SMAD signaling, whereas the
inflammation-dependent expression is mediated primarily
through IL6/JAK/STAT3 signaling (5). BMP63 plays a key role
in iron-dependent hepcidin expression, based on the observa-
tion that circulating iron levels regulate BMP6 expression and
that BMP6 knock-out mice have low hepcidin expression and
show severe iron overloading (6, 7). The regulation of BMP6
expression occurs at a transcriptional level in the liver, stimu-
lated by an iron-rich diet and suppressed by an iron-free diet (8,
9). It was recently reported that the expression of BMP6 occurs
in nonparenchymal cells of the liver, such as Kupffer cells and
sinusoidal endothelial cells (10). These cells sense iron levels
through an uncertain mechanism and secrete BMP6 to modu-
late hepcidin expression in hepatocytes in a paracrine manner.
Secreted BMP6 interacts with BMP receptors type I (ALK2 and
ALK3) and type II (BMPR2 and ACVR2A) expressed by hepa-
tocytes. Various accessory proteins, some of which are specific
to hepatocytes (5), include hemojuvelin (HJV), a Glycosylphos-
phatidylinositol (GPI)-anchor protein that acts as a BMP co-re-
ceptor (11), and the serine protease TMPRSS6 that controls
HJV activity (12). Neogenin aids in the formation of the com-
plex ofHJV-BMPR topromote signaling or to support the activ-
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ity of TMPRSS6 to cleave HJV and suppress the pathway (13).
Recent studies indicate that TMPRSS6 also cleaves ALK2,
ALK3, ACVR2, BMPR2, hemochromatosis protein, and only to
a lesser extent transferrin receptor-2 (TfR2) (14). Hemochro-
matosis protein and TfR2 sense transferrin saturation in the
plasma and contribute to the control of the activation of the
BMP6/SMAD5 pathway (15).
BMP6 signaling involves activation and phosphorylation of
the BMP receptors, followed by phosphorylation of SMAD1/
5/8, the recruitment of SMAD4, and the translocation of the
complex into the nucleus where it binds a response element in
the hepcidin promoter (11). Inflammatory signaling, initiated
by the release of IL6 by liver macrophages, activates the JAK/
STAT pathway in hepatocytes, resulting in STAT3 phosphory-
lation, which then binds the hepcidin promoter and increases
hepcidin expression dependent in part on SMAD4 (16). The
interaction between the IL6 and BMP6 pathways implies that
inhibition of the BMP/SMAD pathway suppresses both iron-
dependent and inflammation-dependent hepcidin activation
(17).
All cells express heparan sulfate proteoglycans (HSPGs), gly-
coproteins that contain one or more heparan sulfate (HS)
chains (Fig. 1A). Plasma membrane and extracellular matrix
HSPGs can act as receptors for cytokines and growth factors, or
as co-receptors for signaling complexes on the cell surface (18).
In the present study we used a direct approach to examine
the role of hepatocyte HS in hepcidin expression and iron
homeostasis by genetic and pharmacologic alteration of HS
in primary human hepatocytes, human hepatoma cells,
murine hepatocytes, and in vivo in mice. The results show
that hepatocyte HS is a master regulator of hepcidin expres-
sion and iron homeostasis.
Results
Hepcidin expression in human hepatocytes depends on
heparan sulfate
To examine if hepcidin expression depends onHS in primary
human hepatocytes, we obtained cells through the Liver Tissue
Cell Distribution System (see “Experimental Procedures”).
BMP6(50ng/ml)stimulated6-foldhepcidinexpression,asmea-
sured by qPCR ofHAMPmRNA, compared with saline-treated
cells (Fig. 1B). Partial degradation of cell surface and extracel-
lular matrix HS with bacterial heparin lyases decreased HAMP
expression significantly, indicating that HS in primary human
hepatocytes facilitates BMP6-dependent induction of hepcidin
expression (Fig. 1B). Similar results were obtained using hepa-
tocarcinoma cells, a model for human hepatocytes (Fig. S1A).
The partial reduction of hepcidinmRNA expression induced
by heparin lyase treatment could reflect incomplete removal of
HS. To obtain additional evidence that HS regulates hepcidin
expression, we silenced EXOSTOSIN 1 (EXT1) and EXT2 in
human hepatocarcinoma cells with siRNAs. EXT1 and EXT2
encode components of the co-polymerase that alternately
transfer glucuronic acid and GlcNAc units during HS chain
elongation (Fig. 1A). Transfection of cells with siRNAs reduced
mRNA levels of EXT1 and EXT2 by 80–90% (Fig. 1C) and
expression of EXT1 and EXT2 proteins (Fig. S1B). Simultane-
ous silencing ofEXT1 andEXT2 caused a dramatic reduction of
HAMP mRNA expression in naive cells and after stimulation
with BMP6 (Fig. 1D). Silencing of EXT1 and EXT2 also reduced
pSMAD5 in unstimulated cells and after stimulation with
BMP6 (Fig. 1, E and F). Expression of ID1 (inhibitor of DNA
binding protein 1), another marker of the BMP6/SMAD path-
way, also was diminished, although not to the same extent (Fig.
1G). Control experiments using siRNA to GFP showed no
impact on expression ofEXT1,EXT2,HAMP, and ID1, or phos-
phorylation of SMAD5 (Fig. 1, C–G). Together, these studies
demonstrate that HS strongly regulates hepcidin mRNA
expression in human hepatocytes.
Sulfation of HS influences hepcidin expression
To study how the structure ofHS influences hepcidin expres-
sion, we inactivatedNDST1 in Hep3B cells using CRISPR/Cas9
gene targeting technology. NDST1 initiates the sulfation of HS
by N-deacetylation and N-sulfation of a subset of GlcNAc res-
idues (Fig. 1A). Downstream processing of the chains by 6-O-
sulfation of glucosamine residues and epimerization and 2-O-
sulfation of uronic acids depends on prior NDST action. Thus,
diminishing NDST1 expression depresses overall sulfation of
the chains. A clonal line (NDST1/) was isolated bearing two
independent frameshift alleles in exon 1 of NDST1 that caused
premature stop codons in both alleles downstream from the
frameshift (Fig. 2A). We noted markedly reduced NDST1
mRNAexpression (82 3% reduction inNDST1/ compared
with WT) (Fig. S1C) and binding of fibroblast growth factor 2
(FGF2) to the mutant, which reflects the loss of cell surface HS,
and the extent of reduction occurred similarly in WT cells
treated with heparin lyases (Fig. 2B). Isolation of HS from the
mutant and depolymerization of the chains into disaccharides
showed that NDST1/ cells exhibited a decrease of disaccha-
rides bearingN-sulfoglucosamine residues (D0S0, D0S6, D2S0,
and D2S6) and accumulation of nonsulfated disaccharides
(D0A0). Overall N-sulfation of glucosamine residues was
reduced by 73%, leading to40% reduction in 6-O-sulfation of
glucosamine residues and 90% reduction of 2-O-sulfation of
uronic acids because of coupling of these downstream reactions
toN-sulfation (Fig. 2C). The reduction of sulfation was incom-
plete because of expression of NDST2 in the cell line, as
observed in other cell types (19–21). Nevertheless, the reduc-
tion in sulfation afforded by inactivation of NDST1 expression
reducedHAMP expression by 70% in the absence of BMP6 and
by 90% after stimulation (Fig. 2D).
Pharmacological studies also demonstrated the dependence
of HAMP expression on sulfation of HS. Sodium chlorate is an
inhibitor of the universal sulfate donor 3-phosphoadenyl-5-
phosphosulfate (PAPS) (22) and blocks sulfation of HS and
other macromolecules. Treatment of hepatoma cells with 50
mM sodium chlorate caused a significant suppression of both
unstimulated and BMP6-stimulated HAMP expression (Fig.
3A). The addition of 25–50 mM NaCl had no effect on HAMP
expression (Fig. S2A), indicating that the inhibitory effect of
sodium chlorate was not because of changes in osmolarity of
the medium.
Recently, we reported that surfen (bis-2-methyl-4-amino-quin-
olyl-6-carbamide) and oxalylsurfen (bis-2-methyl-4-amino-quin-
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olyl-6-oxalylamide) block HS-dependent processes by interfer-
ence with protein-HS interactions (23, 24). Surfen reduced basal
and BMP6 stimulatedHAMP expression inHepG2 cells (Fig. 3B).
The effect was greatly magnified in cells treated with the more
potent analog oxalylsurfen (90% inhibition) (Fig. 3C), whereas
treatment with the inactive analog hemisurfen had no effect on
hepcidin expression (Fig. S2B). Cells treated with these different
pharmacological agents showed reduced SMAD5 phosphoryla-
Figure 1. Genetic and enzymatic reduction of HS reduces hepcidin expression and SMAD5 phosphorylation in human hepatocytes. A, a model for an
HS chain using the symbol nomenclature for glycans (42). B, primary human hepatocyteswere treated for 30minwith a combination of heparin lyases I, II, and
III (gray bars) to decrease cell surface and extracellular matrix HS and then stimulated for 6 h with BMP6 (50 ng/ml). HAMP mRNA was measured by qPCR in
triplicate. The average values obtained were normalized to GAPDH mRNA and then expressed as -fold change over untreated cells (n 2). C, EXT1 and EXT2
mRNAexpressionwas silenced inHepG2cells by transfectionof the corresponding siRNAs. As a control, somecellswere transfectedwith siRNAdirected toGFP
(n 3).D,HAMPmRNA expressionwasmeasured 48 h after silencing of EXT1 and EXT2 (EXT1/2) with orwithout stimulation by BMP6 (10 ng/ml) during the last
6 h (n 3). An siRNA targetingGFP served as a negative control. E and F, Western blotting of pSMAD5 and SMAD5 after silencing EXT1/2 or GFPwith orwithout
stimulation with 10 ng/ml of BMP6. The bands were quantitated by ImageJ software and the values were normalized to SMAD5 as shown in (F). G, the
expression of ID1mRNAwas evaluated 48 h after silencing of EXT1/2 or GFP with or without stimulation by 10 ng/ml BMP6 (n 3). In C, D, and G, the average
values for mRNA expression were normalized to HPRT1 and scaled to the average value obtained from untreated cells.
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tion after BMP6 challenge (Fig. 3, D and E). Together these find-
ings show that interferencewithHS sulfation orHS-protein inter-
actions results in diminished HAMP expression under basal
conditions and after BMP6 stimulation.
Hepatocyte-specific inactivation of Ndst1 inmice reduces
hepcidin expression and results in deficient iron homeostasis
As a segue to studying the impact of altering HS on hepcidin
expression and iron homeostasis in mice, we obtained primary
hepatocytes from control mice (Ndst1f/fAlbCre) and mice
in which Ndst1 was inactivated specifically in hepatocytes
(Ndst1f/fAlbCre) (25). Ndst1f/fAlbCre hepatocytes showed
loss ofNdst1mRNA relative to the housekeeping gene, TATA-
box binding protein (Tbp) (Fig. 4A) and absence of NDST1 pro-
tein (Fig. 4B). Inactivation of Ndst1 diminished basal and
BMP6-stimulatedHampexpression(Fig.4C)andSMAD5phos-
phorylation (Fig. 4D). Sulfation of HS is not completely abol-
ished in Ndst1f/fAlbCre hepatocytes (26); thus the impact of
Ndst1 inactivation onHamp expression in murine hepatocytes
was incomplete, but comparable to the reduction inNDST1/
human hepatoma cells (Fig. 2D).
To study the impact of altering hepatic HS on iron metabo-
lism in vivo, we measured Hamp mRNA, serum hepcidin, and
iron levels in mutant and WT mice fed an iron-balanced diet
(0.2 g/kg of carbonyl-iron) and after 1 and 3 weeks on an iron-
rich diet (8.3 g/kg of carbonyl-iron) (Fig. 5A). Ndst1f/fAlbCre
mice fed an iron-balanced diet exhibited 4-fold lower hepatic
Hamp mRNA expression than control mice (Fig. 5B, 0 time
point). Serum hepcidin did not differ significantly (119  41
versus 192  85 ng/ml) (Fig. 5C, 0 time point). Plasma iron
levels were elevated in Ndst1f/fAlbCre mice (240  20 g/dl
versus 190  35 g/dl, respectively) (Fig. 5D, 0 time point), as
was liver iron content (130 30 ng/mg wet weight versus 76
30 ng/mg wet weight, respectively) (Fig. 5E) and ferritin-iron
(Fig. 5F). No difference in spleen iron content was observed
(Fig. 5G).
Iron overloading increases BMP6 expression (8, 9), thus pro-
viding an in vivo system to study the impact of altering HS in
hepatocytes on hepcidin expression. Iron-loading for 1 week
greatly enhanced both Hamp mRNA and serum hepcidin in
Ndst1f/fAlbCre control mice, whereas the effect was signifi-
cantly less in Ndst1f/fAlbCremice (3.7 0.8 versus 2.2 0.5)
(Fig. 5B, 1week). Serumhepcidin showed a similar trend (850
180 in the mutant versus 460 160 ng/ml in the control mice)
(Fig. 5C). Serum iron levels increased as expected after 1 week
of iron-loading, and their levels were consistently higher in the
Ndst1f/fAlbCre mice (290  15 g/dl versus 250  13 g/dl)
(Fig. 5D). Liver iron content was also elevated in the mutant
compared with the WT after 1 week (140  17 ng/mg wet
weight versus 71 17 ng/mgwet weight, respectively) (Fig. 5E).
After 3 weeks on the iron-rich diet, the values for Hamp
mRNA, serum hepcidin, and liver iron remained elevated, but
the values for the mutant were similar to the control (Fig. 5, B,
Figure2. InactivationofNDST1 inHep3Bcells exhibits reducedhepcidinexpression.A, sequence analysis of a regionwithin exon-1ofNDST1 inWTHep3B
cells and in a cloned cell line obtained by targeting NDST1 by CRISPR/Cas9 (NDST1/). The arrows indicate the start site of the altered DNA sequence in the
mutant and the predicted amino acid sequence. Each allele results in a downstream frameshift mutation. B, FGF2 binding to WT and NDST1/ Hep3B cells.
Loss of NDST1 results in diminished binding of FGF2 to HS. A set ofWT cells were treatedwith heparin lyases I, II, and III (5milliunits/ml) prior to flow cytometry
(n 3biological replicates, eachperformed in duplicate). The datawere analyzedusing one-wayANOVAwith Tukey’smultiple comparison test.C, HS fromWT
(white bars) and NDST1/ (black bars) cells were digested with heparin lyases I, II, and III and the liberated disaccharides were analyzed by LC-MS: D0H6,
	UA-GlcNH26S; D2H0, 	UA2S-GlcNH2; D0A0, 	UA-GlcNAc; D0S0, 	UA-GlcNS; D2H6, 	UA2S-GlcNH26S; D0A6, 	UA-GlcNAc6S; D0S6, 	UA-GlcNS6S; D2A0,
	UA2S-GlcNAc; D2S0, 	UA2S-GlcNS; D2A6, 	UA2S-GlcNAc6S; D2S6, 	UA2S-GlcNS6S; 	UA, 4,5-unsaturated uronic acid (43). Disaccharide analysis was per-
formed on a pool of three sets of cells (n 3 biological replicates that were pooled and analyzed).D, WT andNDST1/ cells were incubatedwith andwithout
BMP6 (50 ng/ml) for 6 h and expression ofHAMPmRNAwasmeasured and normalized to GAPDH (n 2wells). The datawere analyzed using two-way ANOVA
with uncorrected Fisher’s least significant difference post hoc test.
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C, and E). Serum iron levels remained elevated at 3 weeks in the
mutant compared with the WT (Fig. 5D). Ferritin-iron com-
plexes also were significantly elevated in liver samples in the
mutant compared with the control (Fig. 5F). Spleen iron con-
tent rose dramatically with iron loading but showed no differ-
ence between control and mutant mice (Fig. 5G).
Analysis of several proteins related to iron storage and
metabolism showed that liver ferroportin (FPN) and transferrin
receptor (TfR1) did not differ inmutant andWTanimals fed an
iron-balanced diet (Fig. 5H, 0 time point). Under these condi-
tions, ferritin L (FtL) was significantly elevated in the mutant.
Liver pSMAD5 was reduced significantly in the mutant, which
tracked with reduced HampmRNA expression (Fig. 5B) and a
trend toward reduced serumhepcidin (Fig. 5C). Iron loading for
1–3 weeks did not alter expression of FPN or TfR1, but FtL
remained elevated in the mutant (Fig. 5H). pSMAD5 remained
Figure 3. Pharmacological interference of HS-protein interactions blocks HAMP expression. A–C, HepG2 cells were treated with (A) the indicated
concentration of sodium chlorate for 3 days (n 3), (B) 20M of surfen for 24 h (n 3), or (C) with 20M of oxalylsurfen for 24 h (n 3). BMP6 (10 ng/ml) was
added as indicated for the last 6 h of incubation. D, Western blotting of pSMAD5 and SMAD5 after treatment with the indicated concentration of sodium
chlorate for 3 days and BMP stimulation. The bands were quantitated by ImageJ software and the values were normalized to SMAD5 (n  3). E, cells were
treatedwith surfen or oxalylsurfen as indicated and pSMAD5 and SMAD5were determined byWestern blotting (n 3).A–C, values formRNA expressionwere
normalized to HPRT1 in the samples and expressed as the -fold change over untreated cells.
Figure4. ReductionofHAMPexpressionandpSMAD5 inprimaryhepatocytesderived fromNdst1f/fAlbCremice.A, level ofNdst1mRNA inhepatocytes
derived from Ndst1f/fAlbCre (control) and Ndst1f/fAlbCre (mutant) mice. B, level of NDST1 protein. C, level of Hamp mRNA. D, SMAD5 phosphorylation in
primary hepatocytes derived from Ndst1f/fAlbCre and Ndst1f/fAlbCre mice treated with different concentrations of BMP6 for 6 h. Densitometry was per-
formed using ImageJ and the values were normalized to SMAD5 as indicated (n 2).
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Figure 5. Iron metabolism in Ndst1f/fAlbCre mice is altered. A, control Ndst1f/fAlbCre mice and mutant Ndst1f/fAlbCre mice were fed an iron-
balanced diet (IBD) for 1 week (0 time point) and then switched to a iron-rich diet (IRD) for 1 or 3 weeks. B and C, HampmRNA (B) and serum hepcidin (C)
were analyzed at the indicated time points. RNA expression was normalized to Tbp mRNA expression and the values were scaled to the values for the
Ndst1f/fAlbCre control at the 0 time point. D, serum iron was measured at 0, 1, and 3 weeks. E and G, nonheme iron was measured by spectrophoto-
metric assay in (E) liver and (G) spleen. F, representative image of Prussian blue stain and DAB enhancement of ferritin-iron in the liver of Ndst1f/fAlbCre
and Ndst1f/fAlbCremice at 0, 1, and 3 weeks of IRD. H, Western blot analysis of FPN, TfR1, FtL, pSMAD5, and SMAD5. The bands were quantitated with
ImageJ and the values of pSMAD5 were normalized to SMAD5. All other band values were normalized to GAPDH (n 3 mice per group). Each point in
B–F represents individual Ndst1f/fAlbCre (open circles) and Ndst1f/fAlbCre (filled circles) mice. Statistical analysis was performed by two-way ANOVA, t
test and yielded the indicated p values.
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depressed in the mutant (Fig. 5H), consistent with the reduc-
tion in Hamp mRNA expression (Fig. 5B). As expected, Id1
expression increased with iron-loading in WT mice, whereas
mutant mice exhibited no response, suggesting that BMP6 sig-
naling was impaired in the mutant (Fig. S3A). Bmp6 expression
in both control and mutant mice trended toward higher levels
with iron-loading (Fig. S3B).
Modulation of HS decreases inflammation-induced activation
of hepcidin expression
Inflammation also affects hepcidin expression and iron
metabolism, mediated primarily through IL6/JAK/STAT3
signaling (5). To evaluate the impact of altering HS on
inflammation-mediated activation of hepcidin expression,
hepatocytes derived from Ndst1f/fAlbCre and Ndst1f/f
AlbCre animals were exposed to IL6 (50 ng/ml, 6 h). Both
unstimulated and IL6-induced Hamp expression was
reduced in the mutant (Fig. 6A). To confirm these findings,
we treated hepatoma cells with surfen, which reduced IL6-
induced stimulation of HAMP expression (Fig. 6B). Simi-
larly, siRNA-mediated silencing of EXT1 and EXT2 dimin-
ished both baseline and IL6-stimulated HAMP expression,
whereas an siRNA directed against GFP had no effect (Fig.
6C). Surprisingly, silencing of EXT1 and EXT2 had no effect
on STAT3 phosphorylation (Fig. 6D) or suppressor of cyto-
kine signaling 3 (SOCS3) expression, which is downstream
of STAT3 (Fig. 6, E and F). Thus, the IL6 induction of hep-
cidin expression depends on HS, but it occurs independently
of STAT3 phosphorylation and SOCS3 expression.
To examine the impact of an inflammatory challenge in
vivo, we injected Ndst1f/fAlbCre and Ndst1f/fAlbCremice
intraperitoneally with lipopolysaccharide (LPS). Previous
studies have shown that LPS induces a robust increase in
hepatic Socs3 and Hamp mRNA expression as well as a
reduction of serum iron levels in mice (27). LPS induced a
30- to 40-fold increase in Socs3 mRNA expression in both
Ndst1f/fAlbCre andNdst1f/fAlbCremice (Fig. 7A). In con-
trast, Hamp mRNA expression was reduced nearly 3-fold in
Ndst1f/fAlbCremice compared with control mice (Fig. 7B).
This trend was mirrored by reduced serum hepcidin in the
mutant (Fig. 7C). As expected, the reduced hepcidin level in
the mutant after LPS injection was associated with higher
serum and liver iron compared with control mice (Fig. 7, D
and E). Although there was a trend toward reduced spleen
iron in the mutant, the difference was not significant (Fig.
7F), and LPS induced strong STAT3 phosphorylation in both
mice strains (Fig. 7G). These findings suggest that hepatic
HS also plays a key role in the regulation of IL6-induced
hepcidin expression in mice.
Figure 6. HS modulates IL6-induced HAMPmRNA expression in human hepatocytes. A, hepatocytes derived from Ndst1f/fAlbCre and Ndst1f/fAlbCre
micewere treatedwith IL6 (50 ng/ml, 6 h), andHampmRNAwas quantitated by qPCR (n 2). B, HepG2 cells were treatedwith 20M surfen, and IL6 (50 ng/ml)
was added for 6 h. The cells were collected for HAMPmRNA quantification by qPCR (n 4–7). C, HepG2 cells were treated with siRNAs to EXT1 and EXT2 or to
GFP and after 48 h HAMPmRNA expression was measured. IL6 (50 ng/ml) was added during the last 6 h as indicated. D, Western blot analysis of pSTAT3. The
bands were quantitated with ImageJ and expressed relative to STAT3 and then normalized to the values obtained from the untreated control (n 2–4). E,
SOCS3 mRNA expression was measured in HepG2 cells treated with 20 M surfen with and without IL6 (50 ng/ml, 6 h). The values were normalized to HPRT1
expression and scaled to the value obtained in the absence of surfen and IL6 (n 3). F, HepG2 cells were treated with siRNAs to EXT1 and EXT2 or to GFP and
after 48 h SOCS3 mRNA expression was measured. IL6 (50 ng/ml) was added during the last 6 h in some of the cultures. Values for mRNA expression were
normalized to HPRT1 in the samples and expressed as the -fold change over the untreated cells (n 3).
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Figure 7. Reduced sulfation of HS in Ndst1f/fAlbCre decreases Hamp mRNA and plasma hepcidin after LPS injection. Ndst1f/fAlbCre and
Ndst1f/fAlbCre mice were fed an iron-balanced diet for 1 week and then treated with a single intraperitoneal dose of LPS (1 mg/kg). After 6 h, mice were
sacrificed. A, liver Socs3 mRNA level was measured and normalized to Tbp mRNA. B, Hamp mRNA was measured in the liver and normalized to Tbp mRNA. C,
serum hepcidin was measured before and after LPS treatment. D–F, serum iron (D), nonheme liver iron (E), and nonheme spleen iron (F) were measured by a
spectrophotometric assay after PBS or LPS injection. G, hepatic pSTAT3 and pSMAD5 were measured by Western blotting. After quantitation of the bands by
Image J, the values were normalized to STAT3 and SMAD5, respectively. H, Hep3B WT and NDST1/ cells were transfected with pGL2Hamp-luciferase and
pGL2TK-Renilla plasmid along with scrambled siRNA and STAT3 siRNA and stimulated with 50 ng/ml of IL6 for 6 h. Luciferase and Renilla activity were
measured. I, Hep3BWT andNDST1/ cells were transfectedwith pGL2Hamp-luciferase and pGL2TK-Renilla plasmid alongwith scrambled siRNA and SMAD5
siRNA and stimulated with 50 ng/ml of BMP6 for 6 h. Luciferase and Renilla activity weremeasured. n 2 biological experiment done in triplicate. The data in
each of the panels were analyzed by two-way ANOVA with post hoc Bonferroni multiple comparison test.
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The lack of effect of HS on IL6-induced STAT3 signaling
suggested that an alternative pathway might be responsible for
reduced Hamp expression and serum hepcidin. Evaluation of
pSMAD5 in LPS-stimulated WT mice showed a significant
increase, suggesting activation of the pathway. In the mutant,
baseline of pSMAD5 was reduced as shown in Fig. 5H. Impor-
tantly, LPS did not stimulate SMAD5 phosphorylation above
baseline in the mutant (Fig. 7G). To analyze the effect of hepa-
ran sulfate on IL6/STAT3 pathway, we transfected WT and
NDST1-deficientHep3B cells with aHAMP-luciferase reporter
construct and measured luciferase activity upon stimulation
with IL6with andwithout siRNA silencing of STAT3. Silencing
of STAT3 eliminated the heparan sulfate–dependent regula-
tion of IL6-induced HAMP expression as measured by lucifer-
ase activity (Fig. 7H). We performed a similar experiment to
evaluate the impact of NDST deficiency on BMP6/SMAD5
pathway by siRNA silencing of SMAD5. Silencing of SMAD5
did not diminish BMP6-dependentHAMP expression (Fig. 7I).
SMAD5 siRNA and STAT3 siRNA reduced SMAD5 and
STAT3 mRNA levels, respectively, compared with scrambled
siRNA in both WT and NDST1/ cells (Fig. S4, A and B).
Discussion
In this paper, we provide genetic and pharmacological evi-
dence for cell autonomous control over hepcidin expression by
HS in human and murine hepatocytes. Moreover, the modula-
tory effects of HS, demonstrable in cell culture, translate to
altered iron homeostasis in vivo based on the accumulation of
serum and liver iron inmice bearing a hepatocyte specific alter-
ation of HS biosynthesis. Regulation of the system depends not
only on the amount of HS produced, but also on its degree of
sulfation and its capacity to interact with heparan sulfate–
binding proteins.
The studies reported here provide the first direct evidence that
hepatic HS alters iron metabolism. HS affects baseline, BMP6-
stimulated, and IL6-stimulated hepcidin expression, suggesting a
common underlying mechanism. However, siRNA-mediated
reduction of STAT3 expression eliminated HS-dependent reg-
ulation of IL6-induced HAMP-luciferase expression, whereas
siRNA-mediated reduction of SMAD5did not eliminate theHS
dependence of BMP6 signaling.
The observation that surfen, sodium chlorate, and Ndst1
inactivation depressed hepcidin expression suggests that HS
may act as a “ligand” for one or more factors central to iron
regulation. Previous studies showed that exogenous heparin, a
highly sulfated form of HS, inhibits hepcidin expression in hep-
atoma cells and inmice (28–30).Heparin inhibition of hepcidin
expression in cells depends on 2-O-sulfated uronic acids and
N-sulfated/6-O-sulfated glucosamine residues and requires
chains of 7 kDa (31), or 12 disaccharides. Mechanistically,
heparin may block the interaction of BMP6 with type I BMP
receptors, as both the ligand and the receptor bind to heparin
(32–34). In a previous studywe showed that the overexpression
of heparanase, an endo--D-glucuronidase that cleaves HS,
reduced hepcidin expression and increased liver and serum
iron concentration (35). Because heparanase is also involved in
various signaling pathways not directly related toHS, this study
was inconclusive. The results reported in the present paper
were essential to demonstrate the specific role of hepatic HS in
hepcidin expression.
The findings reported here suggest the possibility that
endogenousHS serves as a template to support the formation of
a signaling complex on the cell surface between BMP6 and one
or more BMP receptors. In the liver, this proposed complex
might consist of receptors and protein ligands, as well as ancil-
lary factors such as hemojuvelin and other co-activators of hep-
cidin expression (36). The similar effects of altering HS on
BMP6- and IL6-induced hepcidin expression and iron
homeostasis deserve further study, especially in light of the
observation that altering HS had no effect on SOCS3 expres-
sion or STAT3 phosphorylation. Both systems may depend
on formation of appropriate signaling complexes containing
HS on the plasma membrane. Alternatively, the pathways
may converge intracellularly through SMAD5 phosphorylation,
that is reducedwhen the levels of HS are altered, as demonstrated
in this study.
HS does not typically occur as free chains, but rather as pro-
teoglycans. Thus, identification of the relevant HSPGs in hepa-
tocytes would provide additional insight into the composition
of the functional signaling complex. Hepatocytes express mul-
tiple heparan sulfate proteoglycans, including several mem-
brane proteoglycans (syndecans and glypicans), and the extra-
cellular matrix proteoglycans perlecan, collagen 18, and agrin
(37). Further studies are underway to identify the relevant pro-
teoglycan(s) that modulate BMP6-dependent hepcidin expres-
sion in cells. LPS induces dramatic proteolytic shedding of syn-
decan-1 in the liver (37) but as shown here LPS increases
hepcidin levels (Fig. 7), suggesting the participation of other
proteoglycans in the regulation of hepcidin expression. The
diminished effect of LPS in Ndst1f/fAlbCremice is consistent
with this idea and raises the possibility that other factors that
regulate heparan sulfate proteoglycan expression and/or hepa-
ran sulfate composition could impact iron homeostasis.
Together, our findings introduce HS as a potential therapeutic
target for treating disorders of iron metabolism.
Experimental procedures
Cells
Primary human hepatocytes were obtained from a public
repositorymanaged by the University ofMinnesota under con-
tract from the NIDDK at the National Institutes of Health
(Liver Tissue Cell Distribution System). Cells were derived
from resected liver sample from a 63-year-old female with a
bleeding liver cyst (no chemotherapy history) and seeded in
6-well plates. The human hepatoma cell lines, HepG2 and
Hep3B (American Type Culture Collection), were cultured in
minimum essential medium (MEM, Gibco, Life Technologies)
containing 10% endotoxin-free fetal bovine serum (FBS)
(Sigma-Aldrich), 0.04 mg/ml gentamicin (Gibco), and 2 mM
L-glutamine (Gibco) at 37 °C under an atmosphere of 5% CO2/
95% air. Mouse hepatocytes were isolated from 10-week-old
animals as described previously (38). The cells were counted
and seeded at 5 
 105 cells/well in 6-well plate coated with
collagen (2.5 mg/ml in 0.5 M acetic acid, Sigma-Aldrich).
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Pharmacological treatments
Hepatocytes were seeded in 12-well plates (1.5 
 105 cells/
well) in the presence or absence of different concentrations of
sodium chlorate or NaCl (25–50mM) for 72 h or surfen, oxalyl-
surfen, or hemisurfen for 24 h (24). During the last 6 h, BMP6
(10–50 ng/ml, R&D Systems), IL6 (50 ng/ml, ReliaTech), or
PBS was added. Cells were collected for RNA extraction
and evaluated for mRNA expression by qRT-PCR, or protein
expression by Western blotting.
siRNA silencing and CRISPR/Cas9mutagenesis
HepG2 was seeded in 12-well plates (1 
 105 cells/well) in
MEM with 10% FBS. After 24 h the cells were transfected with
siRNA for Ext1 and 2 or GFP siRNA (10 pmol each per well,
Sigma-Aldrich) with RNAiMax (Life Technologies) according
to the manufacturer’s instructions.
Mutant cell lines lacking GlcNAc N-deacetylase N-sulfo-
transferase-1 (NDST1/) were generated using NDST1 guide
RNAs designed according to Broad Institute published
resources (39) and were synthesized by ValueGene. Guide
RNAs (100 M) were annealed using T4 polynucleotide kinase
(New England Biolabs) and integrated into vector pSp-
Cas9(BB)-2A-Puro (a gift fromDr. Feng Zhang) using T7 ligase
(New England Biolabs). The vectors were sequenced by Sanger
sequencing to confirm their correct construction and trans-
fected into Hep3B cells using Lipofectamine-2000 according to
the manufacturer’s instructions. Transfected Hep3B cells were
selected with puromycin (3 g/ml) and single cell clones were
isolated by limiting dilution. Mutations in the targeted region
were determined by PCR amplification and Sanger sequencing.
Mice
Ndst1f/fAlbCre mice were generated and genotyped as
described previously (25). Mice were weaned at 3 weeks, main-
tained on a 12-hour light/12-hour dark cycle and fed ad libitum
with water and standard rodent chow. All animals were housed
and bred in vivaria approved by the Association for Assessment
and Accreditation of Laboratory Animal Care located in the
School of Medicine of UC San Diego, following standards and
procedures approved by the UC San Diego Animal Subjects
Committee under protocol S99127.
Control Ndst1f/fAlbCre and mutant Ndst1f/fAlbCre mice
(14 weeks old) were maintained on an iron-balanced diet (0.2
g/kg carbonyl-iron; 2Biological Instruments) for 1 week and
then switched to an iron-rich diet (8.3 g/kg carbonyl-iron) for 1
or 3 weeks (4–5 mice per group). To mimic an inflammatory
stimulus, mice were treated intraperitoneally with 1 mg/kg
lipopolysaccharide (Sigma-Aldrich) and euthanized after 6 h.
Blood, liver, and spleen were collected for further analysis.
RNA preparation and qRT-PCR
Total RNA was isolated from tissues or cells using TRIzol
Reagent (Ambion), according to the manufacturer’s instruc-
tions. cDNAwas generated by reverse transcription, using 1g
RNA and SuperScript III Reverse Transcriptase kit (Invitro-
gen). Samples were analyzed by quantitative RT-PCR (qRT-
PCR) using PowerUp SYBR GreenMaster Mix (Life Technolo-
gies) according to the manufacturer’s instructions. All data are
normalized to the expression of the proper housekeeping gene
depending on the type of sample; specifically HPRT1 for
HepG2, GAPDH for Hep3B, and primary human hepatocytes
and Tbp (for murine-derived samples) and expressed by rela-
tive quantificationmethod (2		Ct). The primers are indicated
in Table S1.
Immunoblot analysis and hepcidin ELISA
Mouse tissues or cell extracts were prepared using RIPA
buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, 50 mM Tris-HCl, pH 8, 50 mM DTT, 0.01
mg/ml leupeptin, and Protease Inhibitor Mixture (Roche)) or
using a lysis buffer (200 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1
mM EDTA, 0.5% Nonidet P-40, 10% glycerol, 1 mM sodium
fluoride, 1 mM sodium orthovanadate, and cOmplete Protease
Inhibitor Mixture, Sigma-Aldrich). Protein was quantified
by BCA assay (Thermo Scientific-Pierce). Samples (40–50g
of protein) were separated by 10–14% SDS-PAGE and trans-
ferred to Hybond-P Membrane (GE Healthcare). The primary
antibodies used for immunoblotting were anti-L-ferritin
(Sigma-Aldrich, F5012); anti-GAPDH (OriGene Technolo-
gies, TA802519); anti-phospho-SMAD5 (Abcam, RabMab
AB92698); anti-phospho-STAT3, anti-SMAD5, anti-STAT3
(from Cell Signaling Technology, 9138S, 9517, and 9139,
respectively); anti-actin (OriGene Technologies, TA890010);
anti-TfR1 (Invitrogen, 136800); anti-ferroportin (Abnova, Novus
Biologicals, NBP1–21502); and anti-EXT1, anti-EXT2, and
anti-NDST1 (Santa Cruz Biotechnology, Ext1 Cod. sc-515144,
Ext2 sc-514092, NDST1 Cod. sc-374529). After incubation
with horseradish peroxidase–conjugated secondary antibod-
ies, membranes were developed with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific-Pierce) and
visualized by imaging (Lycor Odyssey). Densitometric analysis
was performed using ImageJ software. Mouse serum hepcidin1
was quantified using Hepcidin Murine-Compete ELISA Kit
(Intrinsic LifeSciences) according to the manufacturer’s
instructions.
Heparan sulfate analysis by liquid chromatography/mass
spectrometry
Heparan sulfate was isolated from the cells as described pre-
viously (40). Briefly, 1
 106 cells were digested with 0.4 g/ml
Pronase (Sigma-Aldrich) at 37 °C for 16 h and crude GAGs
were isolated by anion exchange chromatography using DEAE-
Sephacel (GEHealthcare). The columns were washed with 0.25
MNaCl and the glycosaminoglycans were eluted with 2 MNaCl.
Heparan sulfate chains were depolymerized with heparin lyase
I, II, and III (2 milliunits/ml of each) and unsaturated disaccha-
rides were analyzed using glycan reductive isotope labeling
liquid chromatography/mass spectrometry techniques as
described elsewhere (40).
Iron quantification and Prussian blue staining
Spleen and liver iron content was determined spectrophoto-
metrically as described previously with minor modifications
(41). Briefly, 50mg (wet weight) of tissue was incubated for 18 h
at 65 °C in 3 M HCl and 0.6 M TCA. After centrifugation, sam-
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ples (10 l) of clarified acid extract were added to 240 l of
working chromogen reagent in a 96-well plate (1 volume of
0.1% bathophenanthroline sulfonate/1% thioglycolic acid solu-
tion, 5 volumes of water, and 5 volumes of saturated sodium
acetate). The solutions were then incubated for 30min at room
temperature and the absorbance measured at 535 nm in a plate
reader. A standard curve was prepared with a precalibrated
solution of FeCl3 (Sigma-Aldrich). Blood was collected and
serum iron was determined with a commercial kit (Serum Iron
Kit, Randox Laboratories, Ltd.), according to the manufactu-
rer’s instructions.
Liver homogenates were pretreated at 70 °C for 10 min to
enrich the thermostable ferritins. Samples (equivalent to 50 g
of pretreated protein) were loaded on 8% nondenaturing PAGE
and electrophoresed for 3 h at 160V.The gelswerewashedwith
water and incubated in 2% ferrocyanide and 2%HCl for 1 h. To
enhance the signal, the gels were incubated in 0.025% 3,3-di-
aminobenzidine (Sigma-Aldrich) and 0.05% H2O2 in 20 mM
Tris HCl, pH 7.4, for 15–30 min. The reaction was blocked by
washing with tap water.
HAMP promoter activity
Hepcidin promoter activity was measured as described pre-
viously (29). Briefly, Hep3B WT and NDST1/ cells were
transfected with scrambled, SMAD5, or STAT3 siRNAs, along
with pGL2Hamp-luciferase and pGL2TK-Renilla plasmids
(Promega). After 24 h, cells were treated with BMP6 (50 ng/ml)
or IL6 (50 ng/ml) and incubated for 6 h. Luciferase activities
were measured as described (29).
Statistics
Data are shown asmean S.D. ormean S.E. as indicated in
the figures. Generally, mRNA expression levels were scaled to
control values and exhibited as -fold change or percentage.
Comparison of values between untreated or treated cells and
between Ndst1f/fAlbCre and Ndst1f/fAlbCre mice was per-
formed by unpaired, 2-tailed Student’s t test or two-way
ANOVA.Multiple comparisons were corrected by Tukey’s test
(GraphPad Prism Software). Differences were defined as signif-
icant for p values 0.05 or 0.001, respectively, and values are
shown in the figures.
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